MDX-CTLA-4: Phase I data; Phase II for melanoma and prostate cancer

In a U.S. Phase I study, CTLA-4 antibody blockade increased tumor immunity in some patients previously given therapeutic vaccines that enhance dendritic cell presentation of cancer antigens. In partic...